Arginase-1 - Primary Antibody

Arginase-1 (ARG-1) is a key enzyme of the urea cycle found in liver that catalyzes the conversion of L-arginine into L-ornithine and urea. ARG-1 is a highly specific and sensitive marker of benign and hepatocellular carcinoma (HCC) which is now a key target for the differential diagnosis of HCC from metastatic tumors to the liver (1-3). ARG-1 is very specific and has been shown to be more sensitive than Hep Par 1 and Glypican 3 in hepatocellular carcinomas (1-2).

Arginase-1 is available in the following formats:

Format	Description
Concentrate	0.1, 0.5 mL
Predilute	6.0 mL RTU
UltraLine* – For BenchMark	6.0 mL RTU

Ready to Use Antibodies for Your Roche Instrument

Visit the Biocare Medical website for more information on Arginase-1:

Read More

*UltraLine antibodies are developed solely by Biocare Medical and do not imply approval or endorsement of Biocare’s antibodies by Roche® or VENTANA®.

Biocare and Roche/Ventana are not affiliated, associated or related in any way. Roche®, Ventana®, Benchmark® XT, and Benchmark® Ultra are registered trademarks of Roche.

References:

1. Fujiwara M, et al. Arginase-1 is a more sensitive marker of hepatic differentiation than HepPar-1 and Glypican-3 in fine-needle aspiration biopsies. Cancer Cytopathol. 2012; 120:230-7.

2. Timek DT, et al. Arginase-1, HepPar-1, and Glypican-3 are the most effective panel of markers in distinguishing hepatocellular carcinoma from metastatic tumor on fine-needle aspiration specimens. Am J Clin Pathol. 2012; 138:203-10.

3. Yan BC, et al. Arginase-1: A new immunohistochemical marker of hepatocytes and hepatocellular neoplasms. Am J Surg Pathol. 2010; 34(8):1147-54.